

**Identification of Feeder Vessels in Ocular Surface Neoplasia
using Indocyanine Green Angiography**

Journal:	<i>Current Eye Research</i>
Manuscript ID	NCER-2017-0423
Manuscript Type:	Original Articles
Date Submitted by the Author:	10-Jul-2017
Complete List of Authors:	<p>Brunner, Matthias; St. Paul's Eye Unit, Royal Liverpool University Hospital, Department of Corneal and External Eye Diseases and Liverpool Ocular Oncology Service</p> <p>Steger, Berhard; Medical University of Innsbruck, Department of Ophthalmology</p> <p>Romano, Vito; St. Paul's Eye Unit, Royal Liverpool University Hospital, Department of Corneal and External Eye Diseases</p> <p>Hodson, Martin; St. Paul's Eye Unit, Royal Liverpool University Hospital , Ophthalmic Imaging Department</p> <p>Zheng, Yalin; University of Liverpool, Department of Eye and Vision Science</p> <p>Heimann, Heinrich; St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool Ocular Oncology Service</p> <p>Kaye, Stephen; St. Paul's Eye Unit, Royal Liverpool University Hospital and University of Liverpool, Department of Corneal and External Eye Diseases, Department of Eye and Vision Science</p>
Keywords:	Ocular surface neoplasia, Tumour vasculature, Anterior segment fluorescence angiography, Feeder vessels, Afferent and efferent vessels

Identification of Feeder Vessels in Ocular Surface Neoplasia using Indocyanine Green Angiography

A Preliminary Report

Authors: Matthias Brunner, MD^{1,2}, Bernhard Steger, MD³, Vito Romano, MD^{2,4}, Martin Hodson¹, Yalin Zheng, PhD⁴, Heinrich Heimann, MD, PhD¹, Stephen B. Kaye, MD, FRCOphth^{2,4}

Affiliations:

1. Liverpool Ocular Oncology Service, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
2. Department of Corneal and External Eye Diseases, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
3. Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
4. Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom

Corresponding author:

Matthias Brunner
St. Paul's Eye Unit,
Royal Liverpool University Hospital,
8Z Link, Prescot Street, Liverpool, UK
L7 8XP
Phone: 0151 706 2134
Fax: 0151 706 5861
E-mail: matthias@brunnermail.ch

ABSTRACT

Purpose: To evaluate indocyanine green angiography (ICGA) for the identification and characterization of afferent (feeding) and efferent (draining) vessels in patients with ocular surface neoplasia.

Materials and Methods: Consecutive patients with biopsy-proven benign, pre-invasive or invasive ocular surface tumors of the bulbar conjunctiva were included. Patients underwent anterior segment optical coherence tomography, ICGA, and colour photography for the evaluation of the thickness, location, number and diameter of afferent and efferent vessels of the lesions.

Results: Twenty-two eyes of 22 patients with papillomas (n=4), intra-epithelial neoplasia lesion (n=2) in situ or invasive carcinomas (n=6), nevus (n=5), conjunctival melanocytic intra-epithelial neoplasia lesion (n=1), and in situ or invasive melanomas (n=4) were investigated. Afferent (feeder) vessels were identified in all lesions. There were fewer afferent (3.1 ± 1.6) than efferent (7.5 ± 3.5) vessels per lesion ($p < 0.001$) and the mean diameter was smaller for afferent ($101 \pm 62 \mu\text{m}$, 28-281) than efferent vessels ($137 \pm 51 \mu\text{m}$, 31-652; $p = 0.017$). The number of afferent and efferent vessels was associated with the thickness of the lesion ($p = 0.037$, $p < 0.01$). Lesion filling times differed between benign and invasive or pre-invasive lesions ($p = 0.018$).

Conclusions: ICGA is a useful adjunctive *in vivo* imaging method for the assessment of the vasculature in patients with suspected ocular surface neoplasia.

INTRODUCTION

Characterising the vasculature of neoplastic lesions is important in assessing tumour development, growth and response to treatment.(1) Pathological angiogenesis is a particular hallmark of solid neoplasia. Sufficient supply of oxygen and nutrients is critical for neoplastic cell proliferation and tumour survival.(2) While very small, early stage tumours may obtain their oxygen and nutrients by means of diffusion from surrounding tissue vessels, larger tumors that grow beyond a size of 2 mm³ can no longer be sustained by diffusion and require an internal blood supply.(3) The vasculature of tumours, however, is complex and vessel networks in tumours have unique features that differ fundamentally from those seen in normal vasculature. (4,5) These typically consist of a disorganized labyrinth of vessels which lack the conventional hierarchy of arterioles, capillaries and venules seen in normal vascular networks.(4) Tumour vessels are often tortuous with variable diameters, abnormal bulges and blind ends; sometimes accompanied by arteriolar-venous shunts and plasma channels lacking red blood cells.(6) The vessels are poorly invested with smooth muscle cells and may have a discontinuous endothelial cell lining with an abnormal basement membrane, resulting in increased vessel permeability.(7)

Several imaging methods such as magnetic resonance imaging (MR), computed tomography (CT), positron emission tomography, Doppler ultrasonography, and spectroscopy are used to evaluate vascular networks.(8) In the field of ophthalmology, fluorescein and indocyanine green angiography (FA and ICGA) are a very well established and widely used imaging method for the diagnosis and management of a variety of chorioretinal vascular diseases.(9,10) Anterior segment angiography can also be used to investigate the ocular surface vasculature and has gained growing popularity for the clinical assessment of a variety of corneal and extracorneal ocular surface diseases in recent years.(11,12) The better delineation of vessels compared to biomicroscopic assessment and the capability to identify the afferent and efferent vessels makes this imaging technique an invaluable tool for investigating morphological vessel characteristics and blood flow dynamics in vascularized lesions. (13-15) ICGA and FA in conjunction with objective computer-assisted image analysis

1
2
3 has been demonstrated to provide a reliable method for quantifying vessel change in corneal
4 angiogenesis by measuring vessel parameters such as diameter, length, branch pattern and
5 tortuosity.(13) Leakage of fluorescein using FA may reflect vessel maturity and offer the
6 potential to functionally stage angiogenesis.(16)
7
8

9
10 In contrast to choroidal and retinal lesions, vessel characteristics and haemodynamics in
11 ocular surface tumours are still poorly understood and the clinical and prognostic role of
12 tumour-feeding (afferent) and draining (efferent) vessels remains unknown. In this study we
13 evaluated the use of indocyanine green angiography to identify and assess afferent and
14 efferent vessels in patients with benign and malignant neoplastic lesions of the ocular
15 surface.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

Patients referred to the Liverpool Ocular Oncology Service between March and October 2016 with clinically evident pigmented and non-pigmented tumours of the limbal and extra-limbal bulbar conjunctiva were prospectively recruited. All participants had a detailed slit-lamp biomicroscopy and underwent subsequent anterior segment imaging including colour photography, AS-OCT and indocyanine green angiography during the same visit. Patient demographics (age, gender, ethnicity) and clinical tumour characteristics (size, thickness, location, limbal involvement, pigmentation) were collected using a standardised data collection sheet. Tumours with diffuse margins or indiscernible vessels and tumours with non-bulbar conjunctival location were excluded. All patients underwent excisional or incisional biopsy for histopathology. All specimens were assessed by an experienced pathologist at the pathology department of our institution. For pre-invasive melanocytic neoplasia, the term conjunctival melanocytic intra-epithelial neoplasia (C-MIN) was used (also referred to as PAM with atypia), and the severity of dysplasia was graded using the histopathological classification system (score 1-10) of Damato and Coupland.⁽¹⁷⁾ None of the patients had had previous treatment for their ocular surface tumours. Informed consent was obtained from all subjects and the study was approved by the Institutional Review Board and adhered to the Tenets of the Declaration of Helsinki.

Colour images

Colour images were recorded using a slit lamp mounted digital system (SL-D Digital Slit Lamp; Topcon, Tokyo, Japan) as per our existing protocol for standardised colour images: The entire ocular surface was imaged in all 9 positions of gaze using a 10x to 25x magnification and illumination from a 45 degree angled beam on slit lamp biomicroscopy with a diffuser filter and a variable flash intensity. A total of 18 color images (9 images per eye) were obtained for each patient.

Anterior-segment optical coherence tomography

1
2
3 Anterior segment OCT was performed with an OCT lens in conjunction with the HRA2
4 Scanning Laser Ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany) for
5 thickness measurements of tumours. Cross sectional scans at an angle of 0 and 90 degrees
6 were obtained for every lesion and the measurements were taken at the thickest tumour
7 location.
8
9
10
11
12

13 Indocyanine Green Angiography

14
15 An HRA2 Scanning Laser Ophthalmoscope (*Heidelberg Engineering, Heidelberg, Germany*)
16 with a 20° imaging lens and a focus setting of +32.00D was used for ICGA as previously
17 described.(13,14,16) After intravenous injection of 5ml of 5mg/ml indocyanine green dye
18 (Pulsion Medical Systems, Munich, Germany) into a peripheral arm vein, videography was
19 undertaken for 30 to 60 seconds concentrating on the region of interest (ROI), commencing
20 when the dye fluoresced within the eyelids, usually approximately 10 seconds after the
21 injection (depending on age of the patient and the location of the ROI).(16) Following
22 videography, single-frame ICGA photographs of the ROI including the tumour and
23 surrounding blood vessel fluorescence were captured at a 32 to 34x magnification every 3 to
24 5 seconds for 3 minutes in high-resolution mode incorporating automatic real-time (ART)
25 software.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Image analysis

43 ICGA video frames were used to identify the afferent (feeding) and efferent (draining) vessels
44 of each lesion. Afferent vessels were defined as those vessels in which the dye first
45 appeared with anterograde filling towards the tumour. Efferent vessels were defined as
46 vessels filling in a retrograde fashion away from the tumor during or with a latency to
47 intralesional vessel filling. Lesion filling time was defined as the time interval (in seconds)
48 between first dye appearance in afferent and first dye appearance in efferent tumour vessels.
49 The ICGA images were graded using a subjective quality score of 0 to 4 as previously
50 described (0, no vessel discernible; 1, poor vessel delineation; 2, good vessel delineation; 3,
51
52
53
54
55
56
57
58
59
60

1
2
3 very good vessel delineation; 4, excellent vessel delineation).(13) The two best-quality
4 frames demonstrating, first filling of afferent vessels and then complete filling of efferent
5 vessels were independently assessed by two observers (M.B. and V.R.). The two best-
6 quality frames with complete afferent and efferent vessel filling of the ROI were then selected
7 by the same two observers for calculation of vessel diameters. This was performed using an
8 in-house automated program written in numerical computing language (Matlab R14; The
9 Mathworks Inc., Natick, MA) as described and validated elsewhere.(13) Briefly, the software
10 can detect vessels and extract quantitative information of the detected vasculature by
11 performing a series of image processing tasks mainly including image enhancement,
12 enhancement of vessel structures and conversion to binary images. The pixel resolution
13 (mm/pixel) of the angiographic images, defined as the ratio between the diameter of the
14 cornea (12 mm) and the image diameter of the tumour (or two set landmarks within the
15 lesion) in pixels, was estimated by identifying the limbus to limbus diameter manually and
16 calculation of the pixels number within these landmarks. The vessel diameters were
17 measured within a distance of 0.5 to 1 mm from the tumour margin. The orientation of tumour
18 vessels was categorized as the "same", if the entry and exit points of afferent and efferent
19 vessels at the tumour margin were located less than 90 degrees apart, and as 'opposite', if
20 these were located more than 90 degrees apart.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Statistical analysis

42
43 Data were expressed as means \pm SD. The Shapiro-Wilk test was used to test for non-normal
44 distribution of the data. The Mann-Whitney U test was used to compare vessel number,
45 diameter and lesion filling times. P values of less than 0.05 were considered statistically
46 significant. Levels of agreement were tested using Fleiss' Kappa Statistic (k). Interpretation
47 of levels of agreement were based on that described for two (binary) categories for each
48 patient. A value of <0.2 , k was considered slight, $0.2 < k < 0.4$ fair; $0.4 < k < 0.6$ moderate,
49 $0.6 < k < 0.8$ substantial and $k > 0.8$ as almost perfect. Statistical analyses were performed
50
51
52
53
54
55
56
57
58
59
60

with the Statistical Package for the Social Sciences Software (IBM SPSS Version 22.0 for
MAC; SPSS Inc., Chicago, IL).

For Peer Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Twenty-two eyes of 22 patients (median, 68 years; range, 23-88 years; female-to-male ratio, 6:16) with ocular surface neoplasia of the bulbar conjunctiva were included. The demographic patient data and clinical tumour characteristics are included in *Table 1*. The majority of patients were caucasians (n=16). The examined tumours included 12 squamous lesions (4 papillomas, 2 intra-epithelial neoplasia lesions (CIN 2), 5 in situ carcinomas (CIN 3), 1 invasive carcinoma, SCC), and 10 melanocytic lesions (5 naevi, 1 melanocytic intra-epithelial neoplasia lesion (C-MIN score 3), 1 melanoma in situ, and 3 invasive melanomas). The temporal bulbar conjunctiva was the most common site of involvement (n=11) and the majority of lesions involved the limbus (n=14) with or without corneal extension. Eleven lesions presented with intrinsic pigmentation. The mean largest basal diameter and maximum tumour thickness measured 8.3 ± 3.5 mm (range, 3-16) and 724 ± 299 μ m (range, 346-1217), respectively. All eyes underwent complete excision (n=20) or incisional biopsy (n=2) and histopathological diagnosis was confirmed in all cases (*Table 1*).

Inter-observer agreement for grading the quality of image assessment and was substantial for the selected ICGA frames (k=0.72; p<0.01) and excellent for afferent and efferent vessel identification (k=0.88; p<0.01). The vessel parameters are summarized in *Table 2*. A mean of 3.1 ± 1.6 (range, 1-7) afferent and 7.5 ± 3.5 (range, 2-14) efferent vessels were found per lesion (p<0.001). The ratio of the number of afferent to efferent vessels was 0.49 ± 0.28 (range, 0.17-1.25). Afferent and efferent vessel diameters ranged from 28 to 281 μ m (mean, 101; SD \pm 51) and 31 to 652 μ m (mean, 136; SD, \pm 62), respectively (p=0.2) with a ratio of 0.80 ± 0.35 (range, 0.7-1.6).

Afferent and efferent vessel number and diameter varied among the different patient subgroups, but did not differ significantly between squamous and melanocytic lesions, or between benign and pre-invasive or invasive lesions (*Table 3, supplementary material*).

There were significant associations between the number of afferent ($R^2=0.59$, p=0.037), and efferent (p<0.01) vessels, vessel diameter ($R^2=0.35$, P=0.05) and tumour thickness, but not with the size (largest basal diameter) of the lesion. Intralesional filling times were significantly

1
2
3 longer in benign (3.19 ± 2.20 sec) than pre-invasive (2.49 ± 1.10 sec) or invasive lesions
4
5 (1.95 ± 0.81 sec) ($p=0.018$), and were also dependent on the location of vessel entry and exit
6
7 points at the tumour margins ($p=0.001$).
8

9 In two patients with papillomas, the afferent vessels coiled around large-diameter draining
10
11 vessels (*Figure 1A-C*). In some neoplasms, afferent vessels accompanied efferent vessels,
12
13 biomicroscopically presenting as finer vessels aligning the efferent vessels in a parallel
14
15 fashion (*Figures 2A-C*). In other lesions, afferent vessels were not located in close proximity
16
17 to efferent vessels (*Figures 3A-C*). The discord between afferent and efferent vessel
18
19 diameters was most noticeable in papillomas, as these lesions presented with relatively small
20
21 afferent and larger-diameter efferent vessels compared to other lesions. Of note, none of the
22
23 afferent vessels in the examined lesions showed the increased tortuosity as commonly seen
24
25 in efferent vessels.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

The architecture and haemodynamics of vascular networks has been investigated in various extraocular tumours.(4,5,18) To the best of our knowledge, this is the first study to report the use indocyanine green angiography (ICGA) for identification and evaluation of afferent and efferent vessel parameters in various ocular surface tumors including benign, pre-invasive and invasive lesions. The use of ICGA for the evaluation and treatment of corneal neovascularization has been well documented. (13,14,16) ICGA has been shown to provide excellent vessel delineation and to differentiate afferent and efferent vessels in neovascular corneal networks and in allergic eye disease .(13,14,16,19,20) In this study, the systematic analysis of videoangiography frames enabled us to evaluate the dye appearance dynamics of vascular networks in each lesion. This allowed for consistent identification of afferent vessels, possibly representing tumour-feeding arteries, and their efferent counterparts, presumably representing draining veins. Using the angiographic images it was possible to differentiate afferent and efferent vessels on biomicroscopy and in colour images. Similar to the good imaging of corneal neovascularisation in the presence of scars or exudate, imaging of the tumour vasulature with ICGA was obtained regardless of the thickness of the lesion. This is important as the vasculature of thicker lesions is very difficult to discern with colour photography. Unlike fluorescein, indocyanine green does not show vessel leakage in early filling phases, and as such is more suitable for fluorescence angiographic vessel delineation in ocular surface lesions.

The term 'feeder vessel' is widely used to describe clinical features of ocular surface tumours and usually refers to prominent tumor vessels seen on biomicroscopy. None of the tumour vessels with prominent appearance on colour images represented afferent i.e true feeder vessels in our case series. Our findings would suggest that this terminology may represent a misnomer in a considerable proportion of cases, as it may be impossible to accurately identify the true afferent and efferent tumour vessels based on biomicroscopy or colour images alone. We would therefore suggest that the terms feeder and drainer vessels only be used if confirmed with angiography or other imaging modes which provide 'direction of flow'

1
2
3 information. The presence of feeder vessels has been considered to represent a possible
4
5 risk factor for malignancy in different studies.(21,22) When interpreting these data it has to
6
7 be considered that the presumed feeder vessels in these studies were based solely on
8
9 biomicroscopic findings and may have included afferent and efferent vessels or perhaps
10
11 efferent vessels only.

12
13 The identification of afferent tumour vessels using fluorescence angiography may also have
14
15 potential clinical implications for the perioperative management of ocular surface neoplasia.
16
17 Interestingly, we observed a significant association of lesional vessel filling times and the
18
19 tumour dignity, with longer filling times in benign than in pre-invasive or invasive lesions. We
20
21 hypothesize that these findings may indirectly reflect haemodynamic changes caused by the
22
23 structural vascular heterogeneity in tumours, which may vary with the severity of disease i.e
24
25 grade of dysplasia. Increased structural heterogeneity of vascular networks is a well-known
26
27 feature of neoplastic lesions(5) Vascular networks of tumours contain tortuous vessels,
28
29 shunts, vascular loops, widely variable intervascular distances, and large avascular
30
31 areas(1,4,18), and regions of stagnant or intermittent blood flow within these networks have
32
33 been observed.(23,24)Functional shunts within vascular networks of induced squamous
34
35 carcinoma in a mouse model have been demonstrated using intravital microscopy(5).
36
37 Increased (functional) shunting may also explain the different filling times observed for the
38
39 tumours in our cohort, and as such, may have the potential to be used as diagnostic
40
41 biomarkers for the severity of disease in ocular surface neoplasia.

42
43 Preoperative selective occlusion of afferent vessels with fine needle diathermy
44
45 (FND)(14,25) may reduce intraoperative bleeding during tumor excisions and reduce the risk
46
47 of potential tumour seeding in invasive melanomas. Shutting down the blood supply may in
48
49 addition cause necrosis-induced tumour involution, thereby facilitating the surgical
50
51 management of extensive mass lesions and contributing to the eradication of the tumour.

52
53 There are several limitations to this study. The case numbers were small with lesion
54
55 heterogeneity (diagnosis, size and duration), and in particular there was selection bias; only
56
57 including nodular ocular surface lesions with well-defined tumour margins. Patients with very
58
59
60

1
2
3 extensive or diffuse lesions, and lesions involving the fornix or palpebral conjunctiva, were
4
5 not investigated as such lesions are difficult to approach angiographically. Furthermore, only
6
7 a small proportion of patients presenting with OSN were willing to undergo additional
8
9 examinations including fluorescence angiography for study purposes.

10
11 Despite these limitations we found ICGA to be a useful imaging method for the assessment
12
13 of the vasculature in patients with suspected ocular surface neoplasia arising from the bulbar
14
15 conjunctiva. Angiography enables accurate identification and localisation of afferent and
16
17 efferent vessels and their respective characteristics. As in lesions elsewhere in the body,
18
19 these vascular parameters may be of help in the assessment and management of patients
20
21 with benign and malignant neoplastic lesions of the ocular surface.
22

23
24
25 Funding: None
26

27
28
29 Declaration of Interests: The authors report no conflicts of interest. The authors alone are
30
31 responsible for the content and writing of the paper.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Baish JW, Gazit Y, Berk DA, Nozue M, Baxter LT, Jain RK. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. *Microvasc Res.* 1996 May;51(3):327–46.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature.* 2000 Sep 14;407(6801):249–57.
3. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med.* 1971 Nov 18;285(21):1182–6.
4. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. *Br J Cancer.* 2001 May 18;84(10):1354–62.
5. Pries AR, Cornelissen AJM, Sloot AA, Hinkeldey M, Dreher MR, Höpfner M, et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. *PLoS Comput Biol. Public Library of Science;* 2009 May;5(5):e1000394.
6. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. *Nat Med.* 2003 Jun;9(6):713–25.
7. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WMF. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. *AJPA.* 2003 Jan;162(1):183–93.
8. van Vliet M, van Dijke CF, Wielopolski PA, Hagen ten TLM, Veenland JF, Preda A, et al. MR angiography of tumor-related vasculature: from the clinic to the micro-environment. *Radiographics.* 2005 Oct;25 Suppl 1(suppl_1):S85–97–discussionS97–8.
9. Brancato R, Trabucchi G. Fluorescein and Indocyanine Green Angiography in Vascular Chorioretinal Diseases. *Semin Ophthalmol. Taylor & Francis;* 2009 Jul 2;13(4):189–98.
10. Stanga PE, Lim JI, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. *Ophthalmology.* 2003 Jan;110(1):15–21–quiz22–3.

11. Easty DL, Bron AJ. Fluorescein angiography of the anterior segment. Its value in corneal disease. *British Journal of Ophthalmology*. BMJ Group; 1971 Oct;55(10):671–82.
12. Nieuwenhuizen J, Watson PG, Emmanouilidis-van der Spek K, Keunen JEE, Jager MJ. The value of combining anterior segment fluorescein angiography with indocyanine green angiography in scleral inflammation. *Ophthalmology*. 2003 Aug;110(8):1653–66.
13. Anijeet DR, Zheng Y, Tey A, Hodson M, Sueke H, Kaye SB. Imaging and evaluation of corneal vascularization using fluorescein and indocyanine green angiography. *Investigative Ophthalmology & Visual Science*. 2012 Feb;53(2):650–8.
14. Spiteri N, Romano V, Zheng Y, Yadav S, Dwivedi R, Chen J, et al. Corneal Angiography for Guiding and Evaluating Fine-Needle Diathermy Treatment of Corneal Neovascularization. *Ophthalmology*. 2015 Apr 1;122(6):1079–84.
15. Romano V, Steger B, Zheng Y, Ahmad S, Willoughby CE, Kaye SB. Angiographic and In Vivo Confocal Microscopic Characterization of Human Corneal Blood and Presumed Lymphatic Neovascularization: A Pilot Study. *Cornea*. 2015 Nov;34(11):1459–65.
16. Kirwan RP, Zheng Y, Tey A, Anijeet D, Sueke H, Kaye SB. Quantifying changes in corneal neovascularization using fluorescein and indocyanine green angiography. *Am J Ophthalmol*. 2012 Nov;154(5):850–2.
17. Damato B, Coupland SE. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. *Clin Experiment Ophthalmol*. Blackwell Publishing Asia; 2008 Nov;36(8):786–95.
18. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. *Cancer Res*. 1991 Jan 1;51(1):265–73.
19. Steger B, Romano V, Kaye SB. Angiographic Evaluation of Inflammation in Atopic Keratoconjunctivitis. *Ocul Immunol Inflamm*. 2016 Nov 30;:1–4.
20. Steger B, Romano V, Kaye SB. Corneal Indocyanine Green Angiography to Guide

- 1
2
3 Medical and Surgical Management of Corneal Neovascularization. *Cornea*. 2016
4
5 Jan;35(1):41–5.
6
7 21. Gichuhi S, Macharia E, Kabiru J, Zindamoyen AM, Rono H, Ollando E, et al. Clinical
8
9 Presentation of Ocular Surface Squamous Neoplasia in Kenya. *JAMA Ophthalmol*.
10
11 American Medical Association; 2015 Nov;133(11):1305–13.
12
13 22. Shields CL, Alset AE, Boal NS, Casey MG, Knapp AN, Sugarman JA, et al.
14
15 Conjunctival Tumors in 5002 Cases. Comparative Analysis of Benign versus
16
17 Malignant Counterparts. The 2016 James D. Allen Lecture. *Am J Ophthalmol*. 2016
18
19 Oct.
20
21 23. Chaplin DJ, Hill SA, Bell KM, Tozer GM. Modification of tumor blood flow: Current
22
23 status and future directions. *Seminars in Radiation Oncology*. 1998 Jul;8(3):151–63.
24
25 24. Eskey CJ, Koretsky AP, Domach MM, Jain RK. 2H-nuclear magnetic resonance
26
27 imaging of tumor blood flow: spatial and temporal heterogeneity in a tissue-isolated
28
29 mammary adenocarcinoma. *Cancer Res*. 1992 Nov 1;52(21):6010–9.
30
31 25. Romano V, Steger B, Brunner M, Ahmad S, Willoughby CE, Kaye SB. Method for
32
33 Angiographically Guided Fine-Needle Diathermy in the Treatment of Corneal
34
35 Neovascularization. *Cornea*. 2016 Jul;35(7):1029–32.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1. **A**, Slit-lamp photograph of a 97 year-old male patient showing a conjunctival papilloma, with afferent (black arrows) and efferent (black asterisks) tumour vessels. **B**, Angiographic image of same eye (ICGA, 0:21:64 sec) showing afferent vessels (white arrows). **C**, Angiographic image of same eye showing (ICGA, 0:32:86 sec) efferent vessels (white asterisks).

Figure 2. **A**, Slit-lamp photograph of a 29 year-old male patient showing conjunctival invasive melanoma, with afferent (black arrows) and efferent (black asterisks) tumor vessels. **B**, Angiographic image of same eye (ICGA, 0:12:37 sec) showing afferent vessels (white arrows). **C**, Angiographic image of same eye showing (ICGA, 0:29:35 sec) efferent 'drainier' vessels (white asterisks).

Figure 3. **A**, Slit-lamp photograph of a 55 year-old male patient showing conjunctival and corneal intraepithelial neoplasia (CIN 2), with afferent (black arrows) and efferent (black asterisks) tumor vessels. **B**, Angiographic image of same eye (ICGA, 0:10:28 sec) showing afferent vessels (white arrows). **C**, Angiographic image of same eye showing (ICGA, 0:17:86 sec) efferent vessels (white asterisks).

Table 1. Patient Demographics and Clinical Tumour Characteristics

Patient No. (Gender, Laterality)	Age (Years)	Ethnicity	Histopathological Diagnosis*	Location (Bulbar Quadrant)	Limbal Involvement	Intrinsic Pigmentation	Largest Tumour Diameter [mm]	Tumour Thickness [μ m]
1 (M, OD)	79	Caucasian	Papilloma	Temporal, inferior	yes	no	16.0	980
2 (M, OD)	59	Caucasian	Papilloma	Inferior	no	no	5.1	457
3 (F, OS)	58	Caucasian	Papilloma	Inferior	no	no	10.6	1173
4 (M, OS)	80	Caucasian	Papilloma	Temporal	yes	no	6.7	556
5 (M, OS)	55	African	CIN 2	Temporal, inferior	yes	yes	11.5	549
6 (M, OD)	72	Caucasian	CIN 2	Nasal	yes	no	5.5	1107
7 (M, OS)	64	Caucasian	CIN 3 (CIS)	Temporal	no	no	5.5	673
8 (M, OD)	82	Indian	CIN 3 (CIS)	Temporal	yes	no	8.5	389
9 (F, OS)	86	Caucasian	CIN 3 (CIS)	Nasal, superior	yes	no	10.0	1217
10 (M, OD)	81	Caucasian	CIN 3 (CIS)	Nasal	yes	no	8.0	517
11 (M, OD)	82	Caucasian	CIN 3 (CIS)	Inferior, nasal,	yes	no	11.5	417
12 (M, OS)	75	Caucasian	SCC	Nasal	yes	no	5.8	1160
13 (F, OS)	77	Caucasian	Naevus	Nasal	no	yes	3.7	407
14 (F, OS)	33	Caucasian	Naevus	Nasal	no	yes	11.0	1042
15 (F, OD)	31	Caucasian	Naevus	Superior, temporal	yes	yes	3.0	448
16 (M, OS)	37	Middle-Eastern	Naevus	Temporal	yes	yes	4.9	579
17 (M, OD)	23	Middle-Eastern	Naevus	Temporal	no	yes	9.4	585
18 (F, OD)	63	Hispanic	C-MIN (Score 3) [†]	Temporal	yes	yes	4.6	346
19 (M, OS)	75	Caucasian	Melanoma in situ	Inferior, nasal	yes	yes	15.1	588
20 (M, OS)	88	Caucasian	Melanoma	Temporal, inferior	yes	yes	10.4	731
21 (M, OD)	29	Middle-Eastern	Melanoma	Temporal	no	yes	6.5	923
22 (M, OD)	56	Caucasian	Melanoma	Nasal	no	yes	10.0	1090
Mean	63.0						8.3	724
\pm SD	20.5						3.5	299
Min-Max	23-88						3.0-16.0	346-1217

36 F=female; M=male; OD=right eye; OS=left eye; CIN=conjunctival/corneal intraepithelial neoplasia; C-MIN=conjunctival/corneal melanocytic intraepithelial neoplasia; CIS=squamous cell carcinoma in situ; SCC=invase squamous cell carcinoma.

38 *All patients underwent excisional (n=20) or incisional biopsy (n=2).

39 [†]Classification of C-MIN based on scoring systems (0-10) by Damato and Coupland.

Table 2. Angiographic Parameters of Afferent and Efferent Tumour Vessels

Patient No.	Vessel No.		Mean Vessel Diameters (\pm SD, min-max) [μ m]		Ratio*	Intralesional vessel filling [sec] [†]
	Afferent	Efferent	Afferent	Efferent		
1	3	12	98 (\pm 24, 72-117)	212 (\pm 156, 110-644)	0.46	0.84
2	2	2	95 (\pm 0, 0)	164 (\pm 43, 133-195)	0.58	8.41
3	4	11	174 (\pm 76, 101-281)	208 (\pm 125, 87-520)	0.84	2.95
4	2	8	158 (\pm 96, 90-226)	179 (\pm 63, 83-263)	0.88	3.81
5	1	3	121 (\pm 0, 0)	109 (\pm 18, 95-129)	1.11	0.97
6	3	7	46 (\pm 13, 32-58)	65 (\pm 17, 51-99)	0.71	1.47
7	3	9	115 (\pm 48, 70-166)	135 (\pm 36, 87-202)	0.85	3.67
8	2	2	241 (\pm 22, 226-256)	190 (\pm 4, 188-193)	1.27	2.32
9	4	10	60 (\pm 8, 51-70)	88 (\pm 37, 47-167)	0.68	2.93
10	1	5	64 (\pm 0, 0)	82 (\pm 14, 70-104)	0.78	2.2
11	3	14	38 (\pm 15, 28-49)	144 (\pm 34, 102-192)	0.26	1.37
12	3	7	42 (\pm 6, 36-48)	115 (\pm 69, 62-257)	0.37	1.06
13	3	6	55 (\pm 16, 43-73)	102 (\pm 23, 80-144)	0.54	3.42
14	3	6	40 (\pm 12, 30-54)	130 (\pm 56, 89-222)	0.31	2.54
15	3	7	69 (\pm 26, 44-95)	69 (\pm 17, 52-90)	1.00	1.27
16	5	4	107 (\pm 52, 62-192)	85 (\pm 13, 75-103)	1.26	3.5
17	3	4	108 (\pm 27, 91-140)	136 (\pm 24, 101-157)	0.79	2
18	3	7	94 (\pm 26, 69-121)	81 (\pm 39, 41-138)	1.16	3.5
19	7	10	103 (\pm 20, 74-125)	101 (\pm 16, 82-122)	1.02	4
20	2	12	164 (\pm 71, 113-214)	103 (\pm 30, 31-180)	1.59	2.5
21	7	13	146 (\pm 45, 86-208)	178 (\pm 98, 72-372)	0.82	1.48
22	2	6	91 (\pm 16, 79-102)	332 (\pm 197, 159-652)	0.27	2.75
Mean	3.1	7.5	101.32	136.73	0.80	2.68
\pm SD	1.6	3.5	51.38	62.41	0.35	1.62
Min-Max	1-7	2-14	38-241	65-332	0.26-1.59	0.84-8.41

36 *Afferent to efferent vessels.

37 [†]Defined as time period between first dye appearance in afferent and first dye appearance in efferent vessels (in seconds).

Table 3. Subgroup Comparison of Afferent and Efferent Tumour Vessel Parameters

Subgroups (n)	Mean No. of Vessels (\pm SD, Min-Max)		Mean Vessel Diameters (\pm SD, Min-Max) [μ m]		Ratio*
	Afferent	Efferent	Afferent	Efferent	
Cell type					
Melanocytic (10)	3.8 (\pm 1.9, 2-7)	7.5 (\pm 3.1, 4-13)	0.56 (\pm 0.29, 0.17-1.25)	132 (\pm 77, 69-332)	0.88 (\pm 0.41, 0.27-1.59)
Squamous (12)	2.6 (\pm 1.0, 1-4)	7.5 (\pm 4.0, 2-14)	0.43 (\pm 0.27, 0.20-1.00)	141 (\pm 50, 65-212)	0.73 (\pm 0.29, 0.26-1.27)
P-value	0.1	0.8	0.09	0.2	0.3
Classification					
Benign (9)	3.1 (\pm 0.9, 2-5)	6.7 (\pm 3.3, 2-12)	0.58 (\pm 0.34, 0.25-1.25)	143 (\pm 52, 69-212)	0.74 (\pm 0.30, 0.31-1.26)
Pre-invasive or invasive (13)	3.2 (\pm 1.9, 1-7)	8.1 (\pm 3.7, 2-14)	0.42 (\pm 0.22, 0.17-1.00)	133 (\pm 71, 65-332)	0.84 (\pm 0.39, 0.26-1.59)
P-value	0.5	0.3	0.1	0.4	0.6
Location					
Limbal (14)	3 (\pm 1.6, 1-7)	7.8 (\pm 3.6, 2-14)	0.46 (\pm 0.32, 0.17-1.25)	116 (\pm 47, 65-212)	0.89 (\pm 0.38, 0.26-1.59)
Extra-limbal (8)	3.4 (\pm 1.6, 2-7)	7.1 (\pm 3.6, 2-13)	0.53 (\pm 0.23, 0.33-1.00)	173 (\pm 72, 102-332)	0.63 (\pm 0.24, 0.27-0.85)
P-value	0.5	0.5	0.2	0.04	0.1
Vessel orientation					
Same (14)	3.5 (\pm 1.7, 1-7)	7.9 (\pm 4.0, 2-14)	0.53 (\pm 0.30, 0.17-1.25)	134 (\pm 46, 65-212)	0.81 (\pm 0.40, 0.26-1.59)
Opposite (8)	2.5 (\pm 0.9, 1-4)	6.8 (\pm 2.5, 2-10)	0.42 (\pm 0.25, 0.20-1.00)	141 (\pm 88, 69-332)	0.78 (\pm 0.27, 0.27-1.16)
P-value	0.1	0.5	0.2	0.5	0.9

*Afferent to efferent vessels

†Location of entry and exit points of afferent and efferent vessels at tumour margin (same=within 90 degrees; opposite=more than 90 degrees apart).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. A, Slit-lamp photograph of a 97 year-old male patient showing a conjunctival papilloma, with afferent (black arrows) and efferent (black asterisks) tumor vessels. B, Angiographic image of same eye (ICGA, 0:21:64 sec) showing afferent vessels (white arrows). C, Angiographic image of same eye showing (ICGA, 0:32:86 sec) efferent vessels (white asterisks).

395x117mm (72 x 72 DPI)

Peer Review Only




Figure 2. A, Slit-lamp photograph of a 29 year-old male patient showing conjunctival invasive melanoma, with afferent (black arrows) and efferent (black asterisks) tumor vessels. B, Angiographic image of same eye (ICGA, 0:12:37 sec) showing afferent vessels (white arrows). C, Angiographic image of same eye showing (ICGA, 0:29:35 sec) efferent 'drainier' vessels (white asterisks).

395x118mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. A, Slit-lamp photograph of a 55 year-old male patient showing conjunctival and corneal intraepithelial neoplasia (CIN 2), with afferent (black arrows) and efferent (black asterisks) tumor vessels. B, Angiographic image of same eye (ICGA, 0:10:28 sec) showing afferent vessels (white arrows). C, Angiographic image of same eye showing (ICGA, 0:17:86 sec) efferent vessels (white asterisks).

395x117mm (72 x 72 DPI)

Peer Review Only